Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Thymosin alpha 1 (Zadaxin) in adults with cystic fibrosis
2019-001441-40Phase 2Active
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- May 2021
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymosin alpha 1 in cystic fibrosis (CF), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Primary endpoints: Change in inflammatory cytokines in serum, Change in inflammatory cytokines in induced sputum and 1 more. Started May 2021; status: active.
02
Drugs
thymosin alpha 1
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-001441-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001441-40.